1. Home
  2. TENX vs UTSI Comparison

TENX vs UTSI Comparison

Compare TENX & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TENX
  • UTSI
  • Stock Information
  • Founded
  • TENX 1967
  • UTSI 1991
  • Country
  • TENX United States
  • UTSI China
  • Employees
  • TENX N/A
  • UTSI N/A
  • Industry
  • TENX Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • TENX Health Care
  • UTSI Telecommunications
  • Exchange
  • TENX Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • TENX 27.3M
  • UTSI 24.9M
  • IPO Year
  • TENX N/A
  • UTSI 2000
  • Fundamental
  • Price
  • TENX $6.37
  • UTSI $2.28
  • Analyst Decision
  • TENX Strong Buy
  • UTSI
  • Analyst Count
  • TENX 4
  • UTSI 0
  • Target Price
  • TENX $16.67
  • UTSI N/A
  • AVG Volume (30 Days)
  • TENX 47.8K
  • UTSI 6.0K
  • Earning Date
  • TENX 11-12-2025
  • UTSI 08-29-2025
  • Dividend Yield
  • TENX N/A
  • UTSI N/A
  • EPS Growth
  • TENX N/A
  • UTSI N/A
  • EPS
  • TENX N/A
  • UTSI N/A
  • Revenue
  • TENX N/A
  • UTSI $9,793,000.00
  • Revenue This Year
  • TENX N/A
  • UTSI N/A
  • Revenue Next Year
  • TENX N/A
  • UTSI N/A
  • P/E Ratio
  • TENX N/A
  • UTSI N/A
  • Revenue Growth
  • TENX N/A
  • UTSI N/A
  • 52 Week Low
  • TENX $3.25
  • UTSI $1.84
  • 52 Week High
  • TENX $7.89
  • UTSI $3.22
  • Technical
  • Relative Strength Index (RSI)
  • TENX 69.69
  • UTSI 44.88
  • Support Level
  • TENX $6.02
  • UTSI $2.15
  • Resistance Level
  • TENX $6.50
  • UTSI $2.55
  • Average True Range (ATR)
  • TENX 0.15
  • UTSI 0.15
  • MACD
  • TENX 0.04
  • UTSI -0.03
  • Stochastic Oscillator
  • TENX 78.56
  • UTSI 19.21

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

Share on Social Networks: